CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK

Haematologica

Volumn 94, Issue 6, 2009, Pages 875-880

  Bower, Mark ^a   Fisher, Martin ^b   Hill, Teresa ^c   Reeves, Iain ^b   Walsh, John ^d   Orkin, Chloe ^b   Phillips, Andrew N ^c   Bansi, Loveleen ^c   Gilson, Richard ^c   Easterbrook, Philippa ^e   Johnson, Margaret ^f   Gazzard, Brian ^a   Leen, Clifford ^g   Pillay, Deenan ^h   Schwenk, Achim ⁱ   Anderson, Jane ^j   Porter, Kholoud ^k   Gompels, Mark ^l   Sabin, Caroline A ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UK   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g WESTERN GENERAL HOSPITAL   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ NORTH MIDDLESEX UNIVERSITY HOSPITAL NHS TRUST   (United Kingdom)

^j HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^k MEDICAL RESEARCH COUNCIL   (United Kingdom)

^l NORTH BRISTOL NHS TRUST   (United Kingdom)

more..

Author keywords

CD4 count; Cohort study; HIV; Immunosuppression; Non Hodgkin's lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; RISK FACTOR; UNITED KINGDOM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; YOUNG ADULT;

EID: 66749144914     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.002691     Document Type: Article

References (24)

1. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi's sarcoma and Non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999;319:23-24 (Pubitemid 29304340)
2. Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004;22:2177-2183 (Pubitemid 41095153)
3. Autran B, Carcelain G, Debre P. Immune reconstitution after highly active anti-retroviral treatment of HIV infection. Adv Exp Med Biol 2001;495:205-212 (Pubitemid 34106937)
4. The UK Collaborative HIV Cohort (CHIC) Steering Committee. The creation of a large UK-based multicentre cohort of HIV-infected individuals: The UK Collaborative HIV Cohort (UK CHIC) Study. HIV Med 2004;5:115-124
5. International Collaboration on HIV and Cancer: Highly Active Antiretroviral Therapy and Incidence of Cancer in Human Immunodeficiency Virus-Infected Adults. J Natl Cancer Inst 2000;92:1823-1830
6. Matthews GV, Bower M, Mandalia S, Powles T, Nelson MR, Gazzard BG. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730-2734
7. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406-3412
8. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339-2344
9. Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001;15:629-633 (Pubitemid 32281359)
10. Franceschi S, Dal Maso L, Pezzotti P, Polesel J, Braga C, Piselli P, et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr 2003;34:84-90.
11. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Cancer 2006;106:128-135 (Pubitemid 43032557)
12. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006;20:1645-1654
13. Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008;22:301-306
14. Jacobson LP, Yamashita TE, Detels R, Margolick JB, Chmiel JS, Kingsley LA, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1999;21(Suppl 1):34-41. (Pubitemid 29357647)
15. Carrieri MP, Pradier C, Piselli P, Piche M, Rosenthal E, Heudier P, et al. Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. Int J Cancer 2003;103:142-144 (Pubitemid 35424220)
16. Gasser O, Bihl FK, Wolbers M, Loggi E, Steffen I, Hirsch HH, et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 2007;4:e96. (Pubitemid 46495323)
17. Ling PD, Vilchez RA, Keitel WA, Poston DG, Peng RS, White ZS, et al. Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003;37:1244-1249 (Pubitemid 37372515)
18. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005;97:425-432 (Pubitemid 40528605)
19. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003;32:527-533 (Pubitemid 36423125)
20. Bhaskaran K, Brettle R, Porter K, Walker AS. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS 2004;18:673-681 (Pubitemid 38393467)
21. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006;7:487-503. (Pubitemid 44742349)
22. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843
23. Gazzard B, Clumeck N, d'Arminio Monforte A, Lundgren JD. Indicator disease-guided testing for HIV - the next step for Europe? HIV Med 2008;9(Suppl 2):34-40.
24. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 2003;17:785-820. (Pubitemid 36807598)